Attenuation of Corticosteroid Induced Hippocampal Changes

PHASE4CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Organic Memory Impairment
Interventions
DRUG

Memantine 10 mg capsule

"Memantine oral capsule was initiated at 5 mg/day at Randomization (Week 0), then titrated to 5 mg twice a day at Week 2, then increased to 10 mg in the morning and 5 mg in the evening at Week 3, and then to 10 mg twice a day (intervention dose) at Weeks 4-24. For the participants in the Placebo, then Memantine arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."

DRUG

Memantine-matched Placebo capsule

"Memantine-matched oral Placebo capsule was initiated at Randomization (Week 0) and maintained Weeks 0-24 in a manner consistent with the active drug titration schedule. The number of placebo capsules matched the number of active drug capsules at each titration checkpoint. For the participants in the Memantine, then Placebo arm, the same titration schedule was maintained after the 4-week washout period (Week 28-52)."

Trial Locations (1)

75390-8872

Aston Ambulatory Care Center, Allergy and Immunology, Dallas

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

University of Texas Southwestern Medical Center

OTHER

NCT01656187 - Attenuation of Corticosteroid Induced Hippocampal Changes | Biotech Hunter | Biotech Hunter